BIOCON - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 2.5
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry would be considered around 380-385 ₹, utilizing the immediate support level provided by the recent low of 337 ₹ and the DMA 200 at 397 ₹ as a potential floor. An optimal exit zone would be established between 415-425 ₹, monitoring for signs of profit-taking or increased selling pressure. The stock appears to be trending upwards on high volume, however, the elevated P/E ratio necessitates cautious observation and careful risk management.
✅ Positive
The price is currently trading near its recent high of 447 ₹, suggesting a potential bounce from the immediate vicinity. Volume remains elevated at 79,93,173 compared to the one-week average of 38,94,684, indicating strong buying interest that could sustain this move.
⚠️ Limitation
Despite the high volume and proximity to its recent peak, the stock’s P/E ratio of 208 is significantly higher than the industry PE of 34.8, implying a potentially overvalued situation which could lead to a correction if growth doesn't justify the premium valuation. Additionally, the declining PAT QoQ (729% increase followed by a drop) raises concerns about short-term sustainability and future earnings.
🏭 Industry
The pharmaceutical sector generally enjoys strong investor interest, particularly after recent news of stock splits and buybacks like those seen within the Biocon group alongside others. However, higher P/E ratios are common for companies with high growth potential and innovative drug development pipelines – this is reflected in the industry’s PE ratio of 34.8.